Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Ying ChengXiaodong ZhengXuefu WangYongyan ChenHaiming WeiRui SunZhigang TianHaoyu SunPublished in: Cancer biology & medicine (2020)
The newly generated 161519 TriKE enhanced the proliferation, activation, cytokine secretion, and cytotoxicity of NK cells in the presence of CD19+ tumor cells. The 161519 TriKE aided inhibition of tumor growth and prolonged the overall survival of murine xenografts, and could be used to treat CD19-positive cancers.